Targets › GHR
7 programs from 7 companies in 19 trials: 9 Phase 2, 7 Phase 3, 2 Phase 4, 1 Phase 1; Other, Metabolic and endocrine, Neurology; next expected readout Dec 2026.
Receptor for pituitary gland growth hormone (GH1) involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway..; FUNCTION: [Growth hormone-binding protein]: The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling..; FUNCTION: [Isoform 2]: Up-regulates the production of the soluble Growth hormone-binding protein…. (UniProt, P10912)
Open in Phaseline: the race on GHR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | Somatropin Growth hormone receptor agonist | GHR | Phase 4 | Short Bowel Syndrome (SBS) in Adults; Short Stature Children Born Small for Gestational Age (SGA); Dwarfism; Healthy … | Apr 2027 |
| Novo Nordisk | Somapacitan Growth hormone receptor agonist | GHR | Phase 3 | SGA, Turner Syndrome, Noonan Syndrome, ISS; SGA; Short Stature Children Born Small for Gestational Age (SGA) | Dec 2026 |
| Rabin Medical Center | Somatrogon Growth hormone receptor agonist | GHR | Phase 3 | ISS | Dec 2027 |
| Ascendis Pharma | Lonapegsomatropin Growth hormone receptor agonist | GHR | Phase 3 | Turner Syndrome | Feb 2028 |
| Ascendis Pharma Growth Disorders | Lonapegsomatropin Growth hormone receptor agonist | GHR | Phase 2 | Achondroplasia | Nov 2027 |
| Ascendis Pharma Endocrinology Division | Lonapegsomatropin Growth hormone receptor agonist | GHR | Phase 2 | Turner Syndrome | Dec 2027 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Pegvisomant Growth hormone receptor antagonist | GHR | Phase 2 | Insulin Receptor Mutation | Jan 2028 |
Short Stature Children Born Small for Gestational Age (SGA) (2) Growth Disorders (2) Turner Syndrome (2) SGA, Turner Syndrome, Noonan Syndrome, ISS (1) SGA (1) Short Bowel Syndrome (SBS) in Adults (1) Dwarfism (1) Healthy (1) Preimplantation Genetic Testing (1) Adult Growth Hormone Deficiency (1) Infertility (1) Gulf War Syndrome (1)
protein or peptide (4), small molecule (2), mixed (1)
Novo Nordisk (1) Changchun GeneScience Pharmaceutical (1) Ascendis Pharma Growth Disorders (1) Ascendis Pharma Endocrinology Division (1) Rabin Medical Center (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) Ascendis Pharma (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.